TuHURA Biosciences, Inc. (HURA) Stock

TuHURA Biosciences, Inc. (HURA) is a Healthcare stock trading at $2.00 (as of 2026-08-21), with a market capitalization of $127.13M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

TuHURA Biosciences, Inc. is a cancer immuno-oncology company in the registration-stage clinical development of immunotherapy approaches, focused on technologies intended to address resistance to cancer immunotherapy. The company is headquartered in Tampa, Florida.

Valuation — source: SEC EDGAR (first-party)
Price$2.00
Market Cap$127.13M
Price / Book6.87
FCF Yield-34.8%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$0.00
Return on Equity-165.5%
Debt / Equity0.19
Current Ratio0.18
Financial Health — source: SEC EDGAR
Altman Z-Score0.96 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock, Inc. ($4.39M)
Institutional Holders Tracked10
Congressional Trades (recent)2
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOJames A. Bianco
Employees19
CountryUS
IPO Date2013-02-22

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Equillium, Inc. (EQ)
  • Spruce Biosciences, Inc. (SPRB)
  • Anixa Biosciences, Inc. (ANIX)
  • Genelux Corporation (GNLX)
  • Inovio Pharmaceuticals, Inc. (INO)
  • Neonc Technologies Holdings, Inc. (NTHI)
  • Cumberland Pharmaceuticals Inc. (CPIX)
  • Coya Therapeutics, Inc. (COYA)
HURA earnings history · HURA institutional & insider holders · HURA KPIs & operating metrics · HURA financials · HURA investor presentations & press releases · HURA SEC filings · HURA peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.